These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8020714)

  • 1. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
    Brakman GG
    Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
    Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 5. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective study of inhibitor formation in Japanese hemophiliacs.
    Kamiya T; Takahashi I; Saito H
    Int J Hematol; 1995 Oct; 62(3):175-81. PubMed ID: 8589362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors in congenital coagulation disorders.
    Key NS
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E; Astermark J; Carlborg E
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 12. International workshop on immune tolerance induction: consensus recommendations.
    DiMichele DM; Hoots WK; Pipe SW; Rivard GE; Santagostino E
    Haemophilia; 2007 Jul; 13 Suppl 1():1-22. PubMed ID: 17593277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
    Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
    Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].
    Calvez T; Costagliola D
    Transfus Clin Biol; 1994; 1(6):427-35. PubMed ID: 7881588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic aberrations, HIV seropositivity and seroconversion rates in patients with hemophilia B.
    Brettler DB; Brewster F; Levine PH; Forsberg A; Baker S; Sullivan JL
    Blood; 1987 Jul; 70(1):276-81. PubMed ID: 3109524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience.
    Mathias M; Liesner R; Hann I; Khair K
    Haemophilia; 2005 Jul; 11(4):340-5. PubMed ID: 16011585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of factor VIII and IX inhibitors after first exposure to heat-treated concentrates.
    Hasegawa DK; Edson JR
    Lancet; 1987 Feb; 1(8530):449. PubMed ID: 2880242
    [No Abstract]   [Full Text] [Related]  

  • 18. Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.
    Weatherall J; Barnes N; Brown C; Préaud E
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):411-4. PubMed ID: 21831021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of inhibitors in hemophiliacs with reference to the transfusion of blood products (author's transl)].
    Kamiya T
    Rinsho Byori; 1978; 26(4):291-7. PubMed ID: 671775
    [No Abstract]   [Full Text] [Related]  

  • 20. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.